Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Sales and Divestitures (2019 - 2025)

BridgeBio Pharma's Gains from Sales and Divestitures history spans 7 years, with the latest figure at $1.9 million for Q2 2025.

  • For Q2 2025, Gains from Sales and Divestitures rose 23984.73% year-over-year to $1.9 million; the TTM value through Jun 2025 reached $1.9 million, up 23984.73%, while the annual FY2024 figure was $85453.0, 84.92% down from the prior year.
  • Gains from Sales and Divestitures for Q2 2025 was $1.9 million at BridgeBio Pharma, up from $879051.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.9 million in Q2 2025 and bottomed at $8057.0 in Q1 2024.
  • The 5-year median for Gains from Sales and Divestitures is $388897.0 (2021), against an average of $436640.1.
  • The largest annual shift saw Gains from Sales and Divestitures tumbled 98.65% in 2024 before it skyrocketed 23984.73% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $395672.0 in 2021, then grew by 3.06% to $407786.0 in 2022, then surged by 38.95% to $566605.0 in 2023, then crashed by 84.92% to $85453.0 in 2024, then surged by 2170.85% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Gains from Sales and Divestitures are $1.9 million (Q2 2025), $879051.0 (Q1 2025), and $85453.0 (Q4 2024).